Arm Holdings plc - American Depositary Shares (ARM)

Arm commands premium valuations on its licensing dominance, while Western Digital trades at a steep discount due to the industry's cyclical nature.

The banking giant is still pretty skeptical about Bitcoin.

Brazil stocks tumbled on election news, though not much is changing after the result.

The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.

Astrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the company’s oncology growth strategy. Dave Fredrickson, executive vice president of the company’s o

Xencor (NASDAQ:XNCR) reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for

Dogecoin Labs aims to make the world's first meme coin more useful.

The satellite business model lets Eni expand clean energy without straining core capital allocation.

SpaceX's AI spending plans could translate into $400 billion in revenue for Nvidia next year.

It's a red flag investors would rather not see waving, but most of them may not have put this shift in its proper perspective.

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di

Five consumer companies, five dividend checks, and five projects that will matter more in 2031 than they do today.

Sea Limited is entering the cloud business and is considering spinning off its fintech segment.

Intel can deliver stronger-than-expected results and guidance when it releases its Q3 earnings report on Oct. 29.

This company is entering a massive growth business, but investors didn't want to hear it.

Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology’s Kidney Week meeting in Denver, alongside publication in T

Fee-based federal hubs let NextEra capture data center demand without loading its balance sheet with capital.

Sandisk's shares could get a nice shot in the arm after the company's upcoming earnings report.

Arm Holdings could be the biggest winner of the AI-fueled server CPU boom.

This amazing growth story isn't a matter of lucky timing or rooted in mere wishful thinking.

International Business Machines (NYSE:IBM) reported third-quarter 2026 revenue growth of 6% at constant currency, led by accelerating software sales, infrastructure demand and modest consulting growth. The company said operating pre-tax margin expanded 70 basis points and diluted operating earnings

Investing today in Broadcom, Marvell, AMD, and Arm could produce big returns by 2030.

AI-driven pricing and captive lending are leading the charge toward a 60% SG&A target, which could unlock significant margin expansion.

Is Bitcoin's wild volatility keeping you on the sidelines? BlackRock is building a new buffered ETF designed to smooth out the crypto ride.

The e-commerce and cloud giant already costs more than the average stock. Can it still beat an index fund through 2031?